RESEARCH TRIANGLE PARK, N.C.– Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsized, full-service contract research organization (CRO), announced today that Steve Chriscoe has joined as executive director for oncology project management.
Worldwide continues to invest in the scientific, medical and operations expertise needed to meet the demand of small to midsized biotech and pharmaceutical organizations seeking support for complex oncology studies. Chriscoe, a seasoned project leader with more than 25 years of experience in clinical research and development for the pharmaceutical and biotech industries, is the latest high-profile hire for the company’s rapidly expanding dedicated oncology franchise. Recent executive additions to the team include Clare Wallis as senior vice president, oncology; Emile Youssef, MD, PhD, as vice president, oncology scientific solutions; Gary Fishbein, MD, MPH, as executive medical director, oncology; and Jose L. Martinez, MD, as senior medical director, oncology.
As executive director for oncology project management at Worldwide Clinical Trials, Chriscoe will be responsible for strategic and operational development for the Oncology and Hematology franchises, providing direct management for a number of project leaders globally.
“Our leading reputation among small and midsized biopharma organizations is testament to the extraordinary skill and dedication of project management experts like Steve, who are committed to Worldwide’s vision of being the world’s best midsized CRO,” said Peter Benton, president and chief operating officer, Worldwide. “I know our customers will appreciate his scientific background, knowledge, and regulatory skills in conducting complex oncology clinical research, as well as his passion for delivering outstanding customer service.”
Chriscoe has led oncology clinical research programs for large pharmaceutical, smaller biotech, and CRO organizations. His therapeutic experience includes phases I-III of drug development, with a focus on early phase studies, including first-in-human and dose escalation and expansion studies. He offers deep experience with immune-oncology as well as CART-T therapies, solid tumors (breast, prostrate, bladder, pancreas, head and neck, and liver and lung), and liquid tumors (Non-Hodgkin lymphoma, acute myeloid leukemia and chronic lymphocytic leukemia.)
Chriscoe’s portfolio also extends to studies in all phases of AAV-based gene therapy for rare diseases such as Pompe disease, Huntington’s disease, methylmalonic acidemia (MMA), muscular dystrophy and Angelman syndrome.
Before joining Worldwide, Chriscoe held progressively responsible project management roles at Clinipace, Asklepios BioPharmaceutical, Inc. (AskBio), Chiltern (now Covance Clinical-Biotech), Parexel, GSK, and PPD.
“It’s a very exciting time to join Worldwide, as small and midsized pharma and biotechs are seeking the right CRO partner for their complex oncology studies,” said Chriscoe. “Worldwide has a proven track record for delivering the quality, customer service, and scientific and medical expertise their trial deserves. As demand for our expertise grows, I look forward to contributing to Worldwide’s oncology franchise expansion.”
Chriscoe holds a master’s degree in exercise physiology from the University of North Carolina at Chapel Hill, as well as a bachelor’s degree in physical education from the University of North Carolina at Wilmington.
